Delivery Order SPE2DB24D2003-SPE2DB25FXLH4
- Not listed
- The Defense Logistics Agency awarded a $12,545.94 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) valued at $19,488.02. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 19, 2025, with performance occurring at the vendor's Conshohocken, Pennsylvania headquarters. The contract carries no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to compete...
- The Defense Logistics Agency awarded a delivery order valued at $3,415.62 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count units) on July 14, 2025, with completion expected by July 15, 2025. This firm fixed price delivery order represents a non-competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999.999 billion through December 2026. The product is being delivered to...
- The Defense Logistics Agency awarded a $31,540.49 delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of May 13, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a $29,315.47 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count unit) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $17,816.82 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units). This is a non-set-aside competitive award with an ultimate completion date of September 10, 2025, and represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $41,926.54 for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on August 21, 2025, with completion scheduled for August 22, 2025. This is a firm fixed-price, non-set-aside award that represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order valued at $11,596.65 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-unit package). This firm fixed-price, non-set-aside contract is set for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $5,773.90 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $10,155.29 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count units). This is a firm fixed price, competitively awarded contract with an ultimate completion date of July 29, 2025. The contract carries no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLH4Delivery Order
The Defense Logistics Agency awarded a $10,547.87 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count). This is a competitively awarded, firm fixed-price delivery order with no set-aside designation, due for completion by August 5, 2025. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical support vehicle valued at $999,999,999.00 and running through December 2026. TRELEGY ELLIPTA is a combination respiratory therapy medication used primarily for chronic obstructive pulmonary disease management, supporting the Defense Health Agency and military healthcare systems. AmerisourceBergen leverages its prime indefinite delivery contract to supply a broad range of pharmaceutical products and medical commodities to federal healthcare programs worldwide. The company's extensive federal procurement portfolio demonstrates its capability to meet competitive federal medical supply requirements across multiple therapeutic domains, positioning it as a critical vendor for military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 8/4/25 |